Rarität – Neuroendokrines Karzinom der Mamma

A. Bartens; V. Prasad; S. Maasberg; K. J. Winzer

doi:10.1055/s-0034-1399718

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2015; 36(04): 233-235
DOI: 10.1055/s-0034-1399718

Thieme Onkologie aktuell

Rarität – Neuroendokrines Karzinom der Mamma

A. Bartens

¹Klinik für Gynäkologie und Brustzentrum, Charité Universitätsmedizin Berlin, Charité Campus Mitte

,

V. Prasad

²Klinik für Nuklearmedizin, Charité Universitätsmedizin Berlin, Campus Charité Virchow-Klinikum

,

S. Maasberg

³Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité Universitätsmedizin Berlin, Charité Campus Mitte

,

K. J. Winzer

¹Klinik für Gynäkologie und Brustzentrum, Charité Universitätsmedizin Berlin, Charité Campus Mitte

› Author Affiliations

Abstract

Full Text

References

Literatur
1 WHO classification of tumors of the breast. 2012. Arkh Patol 2013; 75: 53-63
2 Feyrter F, Hartmann G. On the Carcinoid Growth Form of the Carcinoma mammae, especially the Carcinoma solidum (gelantinosum) mammae. Frankf Z für Pathol 1963; 73: 24-39
3 Capella C, Heitz PU, Höfler H et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch Int J Pathol 1995; 425: 547-560
4 Williams GT. Endocrine tumours of the gastrointestinal tract-selected topics. Histopathology 2007; 50: 30-41
5 Miremadi A, Pinder SE, Lee AH et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002; 40: 215-222
6 WHO classification of tumors of the digestive system 2010. IARC 2010 13
7 Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401
8 Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-6020
9 Janni W, Gerber B, Sommer H et al. The management of primary invasive breast cancer. Dtsch Arztebl 2005; 102: A2795-A2804
10 Bodei L, Sundin A, Kidd M et al. The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?. Neuroendocrinology 2014; Sep 10. [Epub ahead of print]
11 AGO-Leitlinie der Kommission Mamma Version 2014. http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/maerz2014/de/2014D_Alle_aktuellen_Empfehlungen.pdf
12 Pavel M, Baudin E, Couvelard A et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176
13 Alkaied H, Harris K, Azab B et al. Primary neuroendocrine breast cancer, how much do we know so far?. Med Oncol 2012; 29: 2613-2618
14 López-Bonet E, Alonso-Ruano M, Barraza G et al. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 2008; 20: 1369-1374
15 Wei B, Ding T, Xing Y et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 2010; 116: 4463-4473
16 Angarita FA, Rodríguez JL, Meek E et al. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol 2013; 11: 128
17 Zhu Y, Li Q, Gao J et al. Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy. Breast J 2013; 19: 382-387
18 Latif N, Rosa M, Samian L et al. An unusual case of primary small cell neuroendocrine carcinoma of the breast. Breast J 2010; 16: 647-651